Indeed, our current study showed that UPK1A-AS1 plays an oncogenic role by modulating EZH2 activity because the downregulation of EZH2 abrogated the tumor-promoting activity of UPK1A-AS1 in HCC. The gene discussed is EZH2; the disease is hepatocellular carcinoma.